Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025

Halle (Saale) / Munich, Germany, August 27, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage entity focused on developing small molecule medications for inflammatory and fibrotic conditions, with a main emphasis on kidney ailments, declared today its intention to release its half-year financial outcomes for the period concluding June 30, 2025, and to provide a corporate update on Thursday, September 4, 2025. The Company will arrange a conference call and webcast that will be accessible to the public. The report itself will be made available for download on the Company’s official website ().

Conference Call Details
Date: September 4, 2025
Time: 3:00 pm CEST / 9:00 am EDT

The conference call can be accessed via telephone and webcast.
A live audio webcast of the call will be streamed on Vivoryon´s website at:

To participate in the conference call by phone, attendees have the option to pre-register and will then receive unique dial-in information for simple and prompt access to the call through the following website:

It is recommended that participants dial into the conference call 15 minutes prior to the scheduled start time to avoid any delays in joining.

###

About Vivoryon Therapeutics N.V.
Vivoryon stands as a clinical-stage biotechnology firm dedicated to creating pioneering small molecule-based treatments for managing inflammatory and fibrotic kidney disorders. Driven by its commitment to cutting-edge science and breakthroughs, the Company strives to enhance patient outcomes by altering the trajectory of severe diseases through modulating the activity and stability of biologically relevant proteins. Vivoryon’s most advanced initiative, varoglutamstat, which is a proprietary, first-in-class orally administered QPCT/L inhibitor, is presently being assessed for the management of diabetic kidney disease.

Vivoryon Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, those pertaining to the business strategy, management plans, and objectives for Vivoryon Therapeutics N.V.’s (the “Company”) future operations, as well as estimates and projections concerning the market for the Company’s products and forecasts and statements about when the Company’s products might become available. Expressions such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should,” and “will,” and similar phrases related to the Company, are used to identify such forward-looking statements. These forward-looking statements do not guarantee future performance; rather, they are based on Management’s current expectations and assumptions regarding future events and trends, the economic climate, and other upcoming conditions. Forward-looking statements inherently involve various known and unknown risks and uncertainties. These risks and uncertainties, along with other factors, could materially and adversely affect the actual outcome and financial implications of the plans and events described herein. The Company’s operational results, cash requirements, financial standing, liquidity, prospects, future dealings, strategies, or events may differ substantially from those expressed or implied in such forward-looking statements and from current expectations. Consequently, undue reliance should not be placed on such forward-looking statements. This press release does not delineate risk factors. Specific risk factors that may influence the Company’s future financial results are discussed in the Company’s published annual financial statements. This press release, including any forward-looking statements within it, is valid only as of its stated date. The Company assumes no obligation to update any information or forward-looking statements contained herein, except as mandated by law.

For more information, please contact:

Investor Relations
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director, Investor Relations & Communication
Email:

LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email:

Media Inquiries
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email:

Attachment